---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-000570"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T22:26:45.514192+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dermata and Revance enter clinical trial collaboration for Xyngari with Daxxify in hyperhidrosis

## Summary
- Dermata and Revance will collaborate on a Phase 2a trial of topical Xyngari with Daxxify for moderate-to-severe axillary hyperhidrosis.
- Trial expected to enroll ~48 patients across US sites; randomized 1:1:1:1, double-blind, placebo-controlled, 16-week evaluation.
- Primary endpoints: ≥50% reduction in gravimetric sweat, absolute change in sweat production, and sweat <50mg.
- If successful, parties may explore additional indications; Xyngari is currently in Phase 3 for acne; Daxxify approved for glabellar lines and cervical dystonia.
- Potential to be first approved needle-free intradermal delivery of a botulinum toxin product.

## SEC filing metadata
- accession: 0001654954-25-000570
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495425000570/0001654954-25-000570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495425000570/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-000570
- JSON: https://secwatch.observer/filing/0001654954-25-000570.json
- Plain text: https://secwatch.observer/filing/0001654954-25-000570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.